Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 2,409 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Invasive Procedure Clear all

Conditions: Movement, Involuntary
Interventions: Philips IntelliVue X3 patient monitor with investigational NIBP measurement algorithm (measured once per 3 minutes); Device
Lead sponsor: Philips Clinical & Medical Affairs Global; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Stroke
Interventions: high frequency rTMS; Device
Lead sponsor: Texas Woman's University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Non-Muscle Invasive Bladder Neoplasms
Interventions: TAR-210, Gemcitabine, MMC; Combination Product · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 641 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 38
States / cities: Little Rock, Arkansas • Los Alamitos, California • Los Angeles, California + 31 more

Conditions: Mild Traumatic Brain Injury, Post Concussion Syndrome
Interventions: Functional near-infrared spectroscopy (fNIRS), V1 stimulation electrodes, Magnetic Resonance Imaging (MRI), MAGNUS scanner; Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 20 Years to 85 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Aspergillosis
Interventions: Micafungin, Liposomal Amphotericin B; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: Not listed
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Ann Arbor, Michigan + 4 more

Conditions: Blood Pressure Measurement
Interventions: Sensifree's Alpha sensor, Arrow® arterial catheterization kit (Teleflex), GE Datex-Ohmeda Oxy-F Finger Clip Pulse Oximeter Sensor; Device
Lead sponsor: Sensifree Ltd.; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Louisville, Colorado

Conditions: Breast Cancer
Interventions: biologic sample preservation procedure, informational intervention; Other
Lead sponsor: GenBasix Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2001
U.S. locations: 1
States / cities: Duarte, California

Conditions: Cognitive Control, Memory
Interventions: Sham device, STARSTIM Device in-phase, STARSTIM Device anti-phase; Device
Lead sponsor: Florida International University; Other
Eligibility: 18 Years to 59 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions: Chemotherapy, Immunotherapy, Laboratory Biomarker Analysis, Lymph Node Biopsy, Ultrasonography; Drug · Other · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 798 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 5
States / cities: Conroe, Texas • Houston, Texas • League City, Texas + 1 more

Conditions: Fungal Infection
Interventions: Prospective TDM Arm; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 12 Years to 100 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Status Asthmaticus
Interventions: Noninvasive positive pressure ventilation; Other
Lead sponsor: Southern Illinois University; Other
Eligibility: 1 Year to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Springfield, Illinois

Conditions: Cervical Cancer, Cervical Cancer Stage, Cervical Cancer Stage IB2, Cervical Cancer Stage IB1, Cervical Cancer Stage I, Cervical Cancer Stage IB, Cervical Cancer Stage II, Cervical Cancer Stage IIa, Cervical Cancer, Stage IIB, Cervical Cancer, Stage III, Cervical Cancer Stage IIIB, Cervical Cancer Stage IIIA, Cervical Cancer Stage Iv, Cervical Cancer Stage IVA, Cervical Cancer Stage IVB
Interventions: Radiation Therapy; Radiation
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Respiratory Insufficiency of Prematurity
Interventions: nCPAP, NIPPV; Device
Lead sponsor: McMaster University; Other
Eligibility: Up to 28 Days
Enrollment: 1,011 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 14
States / cities: Washington D.C., District of Columbia • Boston, Massachusetts • Voorhees Township, New Jersey + 6 more

Conditions: Non-invasive Blood Pressure, Temperature, SpO2, Respiration, ECG
Interventions: Not listed
Lead sponsor: GE Healthcare; Industry
Eligibility: 1 Minute and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2010
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Pain Management
Interventions: Methadone, Standard of Care; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Fall, Gait, Unsteady, Mobility Limitation
Interventions: Transcranial direct current stimulation (tDCS) (active), Transcranial direct current stimulation (tDCS) (Sham); Device
Lead sponsor: Hebrew SeniorLife; Other
Eligibility: 65 Years and older
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Surgery, Hemoglobin
Interventions: Pulse CO-Oximetry Technology, Blood draw; Device · Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 621 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Benign Breast Neoplasm, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Lobular Breast Carcinoma In Situ, Paget Disease of the Breast, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: Docosahexaenoic Acid, Placebo; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 4
States / cities: Boston, Massachusetts • New York, New York • Houston, Texas

Conditions: Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
Interventions: Cretostimogene Grenadenorepvec, n-dodecyl-B-D-maltoside; Biological · Other
Lead sponsor: CG Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 45
States / cities: Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more

Conditions: Neoplasms
Interventions: Indocyanine Green; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Sleep, Sleep Duration, Sleep Quality
Interventions: Deep Sleep (N3) Enhancement with TES; Device
Lead sponsor: Brain Electrophysiology Laboratory Company; Industry
Eligibility: 22 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: Non-muscle Invasive Bladder Cancer
Interventions: TARA-002; Biological
Lead sponsor: Protara Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 10
States / cities: Los Angeles, California • Jacksonville, Florida • New Orleans, Louisiana + 7 more

Conditions: Coronary Artery Disease, Atherosclerosis
Interventions: NIRS/IVUS; Device
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Coronary Disease, Percutaneous Coronary Intervention, Exercise Test, Myocardial Perfusion Imaging, Cardiac Catheterization
Interventions: No study intervention; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

NIBP (Non-invasive Blood Pressure) Algorithm Enhancements (Characterize the Robustness of Motion Artifact Suppression)

Non-invasive Brain Stimulation (NIBS) and Dual-task Walking After Stroke

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

Non-invasive Stimulation of the Glymphatic System for Slowing Cognitive Decline

Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis

Evaluation of Sensifree's Alpha Sensor Signal Morphology Compared to Arterial Line and PPG Signal Morphologies

Blood Sample Collection and Health Information Collection From Patients With Invasive Breast Cancer and Their Brothers and Sisters

Synchronization of Theta to Influence Memory

Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative

A Trial Comparing Efficacy and Safety of Voriconazole Administered With Therapeutic Drug Monitoring vs. Standard Dosing

Non Invasive Positive Pressure Ventilation in Status Asthmaticus

Non-Invasive Cervical Cancer Radiotherapy for Stage IB-IVB

Nasal Intermittent Positive Pressure Ventilation in Premature Infants (NIPPV)

Evaluation Of The GE Monitor Product Line

Methadone Versus Standard of Care for Pain Control in Minimally Invasive Lung Resection Surgery

Non-invasive Brain Stimulation to Improve Unsteady Gait in Older Adults (StimGait)

Accuracy of Pulse CO-Oximetry Technology in Characterizing Noninvasive SpHb

Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Minimally Invasive Imagery With Indocyanine Green

Non-Invasive At-Home Sleep Therapy System

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b)

LipiScan- Ultrasound INterrogation of Atherosclerotic Coronary Arteries:

Fractional Flow Reserve and Instantaneous Free-wave Ratio Revascularization Strategies in Women